SCHEMBL3565469

SCHEMBL3565469

CCOC(=O)c1cnc2c(-c3cccc(Cl)c3)cnn2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.62
KDR P35968 1/20 0.54
KMT2A Q03164 2/20 0.53
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
GPR119 Q8TDV5 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 3/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
STAT1 P42224 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563176 0.83 HPGD (0.71) HPGDKDRKMT2ANPC1RAB9A
SCHEMBL6367566 0.81 HPGD (0.66) HPGDKDRKMT2ANPC1RAB9A
SCHEMBL30184366 0.80 KMT2A (0.53) HPGDKDRKMT2ANPC1RAB9A
SCHEMBL3377441 0.79 NPC1 (0.46) KMT2ANPC1RAB9AGPR119SMN1; SMN2
SCHEMBL3562267 0.79 CYBB (0.54) GPR119GABRA2GABRB2TRPM8CYP1A2
SCHEMBL3561448 0.79 RAB9A (0.65) HPGDKMT2ANPC1RAB9AGPR119
SCHEMBL9172610 0.78 NPC1 (0.51) HPGDKDRNPC1RAB9AGPR119
SCHEMBL9172626 0.78 NPC1 (0.46) HPGDKDRKMT2ANPC1RAB9A
SCHEMBL23675223 0.77 HPGD (1.00) HPGDKDRKMT2ANPC1RAB9A
SCHEMBL13501319 0.75 SLC2A1 (0.63) KMT2ANPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662826-B2 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD. (JP) 2010-02-16 US disclosed
US-7662826-B2 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD. (JP) 2010-02-16 US disclosed
US-20060089362-A1 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD (JP) 2006-04-27 US disclosed
EP-1505068-A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 2005-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089362-A1 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same NADK, PNPO, NQO1 HPGD 14/4885KDR 3317/4885KMT2A 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.